Literature DB >> 17012854

Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates.

Cheryl H Dean1, Jason B Alarcon, Andrea M Waterston, Ken Draper, Richard Early, Farshad Guirakhoo, Thomas P Monath, John A Mikszta.   

Abstract

Flaviviral diseases such as yellow fever, Japanese encephalitis (JE) and dengue hemorrhagic fever cause enormous morbidity and mortality worldwide. There is an urgent need for alternative technologies for mass vaccination against these and other diseases, particularly in the developing world. Here, we administered a live attenuated, chimeric JE vaccine (ChimeriVax)-JE) to nonhuman primates by skin microabrasion and intradermal delivery using microneedles. Both cutaneous delivery methods induced mild viremia similar in magnitude to that observed following subcutaneous (SC) injection. The duration of viremia induced by cutaneous delivery (5-7 days), however, was substantially longer than via SC (0-3 days). In addition, mean neutralizing antibody titers in cutaneous delivery groups were up to 7-fold greater than via SC injection. There were no safety issues identified and both cutaneous delivery methods appeared to be well tolerated. Thus, cutaneous delivery may represent a minimally-invasive alternative approach for flavivirus vaccines that more closely resembles the natural route of viral infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17012854     DOI: 10.4161/hv.1.3.1797

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  33 in total

1.  Coated microneedles for transdermal delivery.

Authors:  Harvinder S Gill; Mark R Prausnitz
Journal:  J Control Release       Date:  2006-10-24       Impact factor: 9.776

Review 2.  Micro-scale devices for transdermal drug delivery.

Authors:  Anubhav Arora; Mark R Prausnitz; Samir Mitragotri
Journal:  Int J Pharm       Date:  2008-08-30       Impact factor: 5.875

Review 3.  Controlled delivery systems: from pharmaceuticals to cells and genes.

Authors:  Elizabeth Rosado Balmayor; Helena Sepulveda Azevedo; Rui L Reis
Journal:  Pharm Res       Date:  2011-03-19       Impact factor: 4.200

4.  Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs.

Authors:  Alfred J Harvey; Scott A Kaestner; Diane E Sutter; Noel G Harvey; John A Mikszta; Ronald J Pettis
Journal:  Pharm Res       Date:  2010-03-31       Impact factor: 4.200

Review 5.  The success of microneedle-mediated vaccine delivery into skin.

Authors:  Sarah Marshall; Laura J Sahm; Anne C Moore
Journal:  Hum Vaccin Immunother       Date:  2016-04-06       Impact factor: 3.452

Review 6.  Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.

Authors:  Veaceslav Boldescu; Mira A M Behnam; Nikos Vasilakis; Christian D Klein
Journal:  Nat Rev Drug Discov       Date:  2017-05-05       Impact factor: 84.694

7.  Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.

Authors:  Mark K Slifka; Donald Y M Leung; Erika Hammarlund; Hans-Peter Raué; Eric L Simpson; Susan Tofte; Shahana Baig-Lewis; Gloria David; Henry Lynn; Rob Woolson; Tissa Hata; Henry Milgrom; Jon Hanifin
Journal:  J Allergy Clin Immunol       Date:  2013-12-10       Impact factor: 10.793

8.  Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.

Authors:  John A Mikszta; John P Dekker; Noel G Harvey; Cheryl H Dean; John M Brittingham; Joanne Huang; Vincent J Sullivan; Beverly Dyas; Chad J Roy; Robert G Ulrich
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

9.  Rational design of a flavivirus vaccine by abolishing viral RNA 2'-O methylation.

Authors:  Shi-Hua Li; Hongping Dong; Xiao-Feng Li; Xuping Xie; Hui Zhao; Yong-Qiang Deng; Xiao-Yu Wang; Qing Ye; Shun-Ya Zhu; Hong-Jiang Wang; Bo Zhang; Qi-Bin Leng; Roland Zuest; E-De Qin; Cheng-Feng Qin; Pei-Yong Shi
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

Review 10.  Microneedle-based vaccines.

Authors:  Mark R Prausnitz; John A Mikszta; Michel Cormier; Alexander K Andrianov
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.